Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.63 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.63 |
| ▸ | MMP8 known ✓ | P22894 | 5/20 | 0.47 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.96 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | MMP14 | P50281 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21491012 | 1.00 | PSIP1 (0.96) | PSIP1CA2CA1GAAMAPT | |
| SCHEMBL506696 | 0.98 | PSIP1 (1.00) | PSIP1CA2CA1GAAMAPT | |
| Hydrochloric Acid SCHEMBL30075994 | 0.86 | PSIP1 (0.71) | PSIP1CA2CA1GAAMAPT | |
| Hydrochloric Acid SCHEMBL22227731 | 0.83 | PSIP1 (0.68) | PSIP1CA2CA1GAAMAPT | |
| SCHEMBL3882769 | 0.83 | PSIP1 (0.74) | PSIP1CA2CA1GAAMAPT | |
| Trifluoroacetic Acid SCHEMBL5758188 | 0.82 | PSIP1 (0.71) | PSIP1CA2CA1GAAMAPT | |
| SCHEMBL28284913 | 0.82 | PSIP1 (0.72) | PSIP1CA2CA1MAPTCA9 | |
| SCHEMBL10767902 | 0.81 | PSIP1 (0.70) | PSIP1CA2CA1GAACA9 | |
| SCHEMBL10455034 | 0.81 | PSIP1 (0.74) | PSIP1CA2GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL353075 | 0.80 | CA2 (0.65) | PSIP1CA2CA1MAPTCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| CN-109485595-B | Hydrophilic group substituted indole formamide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| WO-2021139599-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| WO-2018116285-A1 | SUBSTITUTED MORPHOLINE DERIVATIVES AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-06-28 | — | — | WO | disclosed |
| EP-3331876-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2018042342-A1 | 1,2,3-BENZOTRIAZOLE DERIVATIVES AS ROR GAMMA T MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-9868748-B2 | Thiazolopyrrolidine inhibitors of ROR- γ | VITAE PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845308-B2 | Isoindoline inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | CA2 2516/4885GAA 1530/4885MMP8 3148/4885 |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CA2 2494/4885GAA 1078/4885MMP8 4418/4885 |
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | CA2 2803/4885GAA 694/4885MMP8 4234/4885 |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | CA2 1852/4885GAA 1756/4885MMP8 4003/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | CA2 2413/4885GAA 805/4885MMP8 4258/4885 |
| US-20170008910-A1 | THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CA2 1516/4885GAA 504/4885MMP8 4089/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | CA2 2320/4885GAA 1518/4885MMP8 4374/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CA2 1890/4885GAA 1663/4885MMP8 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.